Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DTPA-A″-CHX-αCD133
- Development stage
- Preclinical
- Lead developer
- Columbia University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DTPA-A″-CHX-αCD133 is a **radiolabeled monoclonal antibody conjugate** designed for targeted radioimmunotherapy. It consists of the αCD133 antibody (targeting the cell surface antigen CD133) conjugated via a DTPA-A″-CHX chelator to the beta-emitting radioisotope Lutetium-177. The compound targets CD133, a protein overexpressed on many cancer stem cells and various tumors, including small-cell lung cancer (SCLC). Upon binding to CD133-positive cells, it delivers localized beta particle radiation, resulting in DNA damage and cell death, with demonstrated dose-dependent anti-tumor effects in preclinical models. It is being developed primarily for cancer indications where CD133 is a relevant biomarker, especially SCLC[1][4].
- Other names
- [177Lu]Lu-DTPA-A″-CHX-αCD133
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on [177Lu]Lu-DTPA-A″-CHX-αCD133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DTPA-A″-CHX-αCD133.